Elizabeth Ann Fagan
Direktor/Vorstandsmitglied bei Perspectum Group Ltd.
Profil
Elizabeth Ann Fagan is currently a Director at Perspectum Group Ltd.
and a Professor at Rush University Medical Center.
She previously worked as a Director at Gilead Sciences, Inc., Encysive Pharmaceuticals, Inc., InterMune, Inc., Tanox, Inc., and Tali Digital Ltd.
Dr. Fagan received her undergraduate, graduate, and doctorate degrees from King's College London.
Aktive Positionen von Elizabeth Ann Fagan
| Unternehmen | Position | Beginn |
|---|---|---|
Perspectum Group Ltd.
 Perspectum Group Ltd. Packaged SoftwareTechnology Services Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom. | Direktor/Vorstandsmitglied | 15.06.2021 |
Rush University Medical Center
 Rush University Medical Center Medical/Nursing ServicesHealth Services Rush University Medical Center engages in the provision of health care services. The company was founded in 1972 and is headquartered in Chicago, IL. | Corporate Officer/Principal | 01.01.1994 |
Ehemalige bekannte Positionen von Elizabeth Ann Fagan
| Unternehmen | Position | Ende |
|---|---|---|
| INTERMUNE INC | Direktor/Vorstandsmitglied | 01.01.2015 |
| GILEAD SCIENCES, INC. | Direktor/Vorstandsmitglied | 01.01.2010 |
| TALI DIGITAL LIMITED | Direktor/Vorstandsmitglied | 01.01.2008 |
Encysive Pharmaceuticals, Inc.
 Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Direktor/Vorstandsmitglied | 01.01.2007 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Direktor/Vorstandsmitglied | 01.01.2005 |
Ausbildung von Elizabeth Ann Fagan
| King's College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| TALI DIGITAL LIMITED | Technology Services |
| Private Unternehmen | 5 |
|---|---|
Perspectum Group Ltd.
Perspectum Group Ltd. Packaged SoftwareTechnology Services Perspectum Group Plc engages in the sale of diagnostic products via a software-as-a-medical device platform. Its products combine expertise in image formation, magnetic resonance image analysis and artificial intelligence to support healthcare provider diagnosis, treatment decision-making, and monitoring of the progression of chronic metabolic diseases, multi-organ pathologies and cancer, and determine whether the patient is responding to therapy. Its products include Liver MultiScan, MRCP+, Hepatica, and CoverScan MD. The company was founded by Matthew Robson on June 10, 2021 and is headquartered in Oxford, the United Kingdom. | Technology Services |
Rush University Medical Center
Rush University Medical Center Medical/Nursing ServicesHealth Services Rush University Medical Center engages in the provision of health care services. The company was founded in 1972 and is headquartered in Chicago, IL. | Health Services |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Encysive Pharmaceuticals, Inc.
Encysive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Encysive Pharmaceuticals, Inc. discovers, develops and markets drugs for the treatment of cardiovascular, vascular and related inflammatory diseases. The firm focuses its research and development programs on the treatment and prevention of interrelated diseases of the vascular endothelium, inflammatory cascade and vascular diseases. The company was founded by James T. Willerson in 1989 and is headquartered in Houston, TX. | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
